Form 4: Bay Shore Trust Reports Acquisition of Telomir Pharmaceuticals Stock Options

Bay Shore Trust, a 10% owner of Telomir Pharmaceuticals, acquired 100,000 stock options at a price of $3.73 per share.

Summary

• Bay Shore Trust, a significant shareholder of Telomir Pharmaceuticals, has reported acquiring 100,000 stock options.
• The options have an exercise price of $3.73 per share.
• The transaction occurred on November 21, 2024.
• The options were granted on June 15, 2023, and expire on June 15, 2028.
• The trust also reported owning 2,339,025 shares of common stock indirectly.
• The shares were acquired via a bona fide gift with no compensation given to the donor.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, and the acquisition of stock options by a major shareholder is generally viewed as neutral to slightly positive.

Positives

• The acquisition of stock options by a major shareholder could be seen as a positive sign of confidence in the company's future.

Risks

• The document does not provide any specific risks.

Industry Context

This is a standard SEC Form 4 filing, which is common for reporting changes in beneficial ownership by company insiders and major shareholders. It is a routine part of regulatory compliance for publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The reporting of stock option acquisitions by a major shareholder is a common occurrence and is comparable to similar filings by other companies.

Stakeholder Impact

• The acquisition of stock options by a major shareholder may be viewed positively by other shareholders.

Key Dates

Keywords

stock options, beneficial ownership, Telomir Pharmaceuticals, Bay Shore Trust, Form 4, insider trading, equity securities